Arcturus Therapeutics Holdings Inc.

ARCT Healthcare Biotechnology

Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS fell 147.1% and free cash flow fell 245.7%, each against the same quarter a year earlier.

10.34 0.93 −8.25%
Market cap
$320.3M
P/E
0.0×
Fwd P/E
−1.9×
Dividend yield
—
F-score
2/9
Altman Z
−0.61
Beneish M
−1.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
5.13 2.05 4.01 6.50
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(29.22) (10.35) (11.29) (9.59)
P/B ratio
2.23 0.78 1.15 1.11
EV/Sales
3.50 0.15 1.53 2.56
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(5.82) (0.17) (1.43) (1.03)
Current Ratio
7.86 6.64 6.31 5.88
Net Debt/EBITDA
14.94 7.54 7.48 7.69
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(13.35%) (38.83%) (36.40%) (49.26%)
Free Cash Flow Yield
(11.70%) (44.38%) (26.72%) (38.10%)
Free Cash Flow per Share
(0.64) (0.59) (0.68) (0.70)
Book value per Share
8.26 7.81 6.73 6.04
Free Cash Flow
(17.33) (16.14) (19.41) (19.89)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates